ClinicalTrials.gg
RecruitingNCT07505667Updated Apr 1, 2026

Yiyuancong for the Treatment of Sudden Sensorineural Hearing Loss

An interventional study of Standard treatment combined with Yiyuancong and Standard treatment in Sudden Hearing Loss and Sensorineural Hearing Loss, sponsored by Guangdong Provincial People's Hospital. Recruiting at 5 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Guangdong Provincial People's Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Nov 2025, registered Mar 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Hearing Loss, Sudden with a site in China — 11 open to participants now, 11 under way, 1 of them phase 3. Hearing Loss, Sudden · China.

Planned enrollment
5th of 15
128 · median 90
Started
2025
with 2 others
No phase
7 of 18
3 open now
Primary completion
2027-11
later than 5 of 10 live
Registered
14th of 18
by date
Lead sponsor
1 of 18
Guangdong Provincial People's Hospital

Among the 18 studies in Hearing Loss, Sudden with a site in China, this one is the 5th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2025, is one of 7 with no phase, reaches primary completion later than 5 of the 10 other live ones, and was the 14th registered.

Hearing Loss, Sudden

66 studies on the registry are indexed under Hearing Loss, Sudden; 25 are open to participants now.

Browse Hearing Loss, Sudden studies →

Open to participants now

11 of the 18 studies in Hearing Loss, Sudden with a site in China are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 10 Hearing Loss, Sudden studies recruiting now, 3 (30%) set no upper age limit and 5 (50%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Hearing Loss, Sudden with a site in China, or all of them as a file.
02

Study summary

This project aims to evaluate the clinical efficacy of Yiyuancong, an independently developed traditional Chinese medicine (TCM) formula based on the homology of medicine and food, in participants with sudden sensorineural hearing loss (SSNHL) and to elucidate its potential underlying mechanisms. This study is designed as a multicenter, randomized controlled trial (RCT), utilizing dynamic randomization for participant allocation. Due to the requirement for the experimental group to continuously administer the TCM preparation for 1-2 months, this study is conducted as an open-label (non-blinded) trial. All participants will undergo audiological evaluations at baseline, day 7 of treatment, and upon completion of the first and second treatment courses.

Based on previous research regarding integrated traditional Chinese and Western medicine for SSNHL, the estimated effect size (ES) for the improvement of pure-tone thresholds compared with Western medicine alone ranges from 0.5 to 0.8. Assuming an effect size of 0.5 for the difference in pure-tone audiometry (PTA) improvement between the experimental and control groups, with a significance level (α) of 0.05 (one-tailed) and a statistical power (1-β) of 0.8, the required sample size calculated via G*Power software is 51 per group. Accounting for a 20% dropout rate, the investigators plan to enroll 64 participants per group (total N = 128).

03

Conditions studied

  • Sudden Hearing Loss
  • Sensorineural Hearing Loss
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Unilateral sudden sensorineural hearing loss (SSNHL) occurring within 72 hours, with a hearing threshold decrease of 20 dB at at least two consecutive frequencies.
  2. Enrollment must be completed within 14 days of the onset of SSNHL.
  3. Males or females aged 18 to 60 years.
  4. Ability to understand the study protocol and comply with regular follow-up visits.

Exclusion criteria

Exclusion Criteria:

  1. Pregnancy or lactation (breastfeeding).
  2. History of chronic ear disease, prior ear surgery, hearing loss, or a confirmed diagnosis of Meniere's disease.
  3. Receipt of therapy for any reason within the previous 30 days.
  4. Presence of autoimmune diseases or chronic inflammatory diseases.
  5. Severe hepatic or renal impairment.
  6. Any other condition that, in the opinion of the investigator, renders the participant unsuitable for inclusion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
128 participants (estimated)

Study arms

  • Experimental
    Standard treatment combined with 15 mL of Yiyuancong herbal paste, taken twice daily after meals

    Drug: Standard treatment combined with Yiyuancong

  • Active comparator
    Standard treatment

    Drug: Standard treatment

Interventions

  • DrugStandard treatment combined with Yiyuancong

    Standard treatment combined with 15 mL of Yiyuancong herbal paste, taken twice daily after meals

  • DrugStandard treatment

    Standard treatment

06

What researchers measure

Primary outcomes

  1. Change in Pure-Tone Audiometry Hearing Threshold (dB HL)

    Change in hearing threshold levels measured in decibels hearing level (dB HL) across standard audiometric frequencies (0.25-8 kHz) using calibrated pure-tone audiometry. Lower dB HL values indicate improved auditory sensitivity.

    Time frame: baseline (day of enrollment), and Day 7, Month 1, and Month 2 post-treatment.

Secondary outcomes

  1. Speech Recognition Score (Word Recognition Percentage)

    Speech recognition ability measured using standardized word recognition testing (e.g., NU-6 word lists). Scores range from 0-100%, with higher scores indicating better speech discrimination ability.

    Time frame: baseline, and Day 7, Month 1, and Month 2 post-treatment.

  2. complete blood count (CBC)

    Time frame: baseline, and Day 7, Month 1, and Month 2 post-treatment.

  3. Haematological index on kidney function

    The investigators assess the changes in haematological index on kidney function levels compared to the baseline. The indicators for evaluating kidney function include biochemical parameters such as serum creatinine, urea nitrogen, uric acid, glomerular filtration rate, and urine protein.

    Time frame: baseline, Month 1, and Month 2 post-treatment.

  4. Haematological index on liver function

    The investigators assess the changes in haematological index on liver function and kidney function levels compared to the baseline. The indicators for evaluating liver function include biochemical indicators such as albumin, transaminases, and bilirubin.

    Time frame: baseline, Month 1, and Month 2 post-treatment.

  5. Fecal composition analysis

    16S rDNA sequencing and bioinformatic analysis were performed on fecal samples collected before and after treatment to identify significantly altered gut microbiota. By comparing microbial diversity, abundance, and function across these time points, the regulatory effects of the Yiyuancong compound on the intestinal microecology were preliminarily explored

    Time frame: baseline, and Month 2 post-treatment.

  6. Peripheral venous blood composition analysis

    Liquid chromatography-mass spectrometry (LC-MS) was employed to perform qualitative and quantitative analysis of the active constituents and metabolites in the patients' plasma. By integrating the results of metabolomics and transcriptomics, the primary active components and potential biological targets of the Yiyuancong compound were further validated.

    Time frame: Baseline, Month 1 and Month 2 post-treatment

07

Study locations

5 of 5 sites recruiting
  • Guangdong Provincial People's Hospital
    Guangzhou, Guangdong, China
    Recruiting
  • Shenzhen Baoan People's Hospital
    Shenzhen, Guangdong, China
    Recruiting
  • Xiaolan People's Hospital of Zhongshan
    Zhongshan, Guangdong, China
    Recruiting
  • Liuzhou Worker's Hospital
    Liuzhou, Guangxi, China
    Recruiting
  • Guangdong Provincial People's Hospital Ganzhou Hospital
    Ganzhou, Jiangxi, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Nov 2027, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 21, 2026
First posted
Apr 1, 2026
StartActual
Nov 15, 2025
Primary completionEst.
Nov 15, 2027
CompletionEst.
Nov 15, 2027
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07505667
Responsible party
Xiong hao (MD, PhD, Guangdong Provincial People's Hospital) — Principal investigator
First posted
Apr 1, 2026
Start date
Nov 15, 2025
Primary completion
Nov 15, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Apr 1, 2026

Study contacts

Zhuoyi Chen MD
Contact
18737552662@163.com
+86 18737552662

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion